The liquid biopsy concept has been introduced for circulating tumor cells more than 10 years ago (Pantel & Alix-Panabieres, 2010) and rapidly extended to cell-free DNA released from tumor cells (ctDNA; Lo et al, 2021) and other tumor-derived products such as circulating cell-free RNA (noncoding and messenger RNA), extracellular vesicles, or tumor-educated platelets (Alix-Panabières & Pantel, 2021). In this issue of EMBO Molecular Medicine, the report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.

中文翻译：

---

液体活检：异种移植物中循环游离 DNA 的血液分析

液体活检概念已在 10 多年前被引入循环肿瘤细胞 (Pantel & Alix-Panabieres, 2010)，并迅速扩展到肿瘤细胞 (ctDNA; Lo et al , 2021) 和其他肿瘤细胞释放的无细胞 DNA。衍生产品，例如循环无细胞 RNA（非编码和信使 RNA）、细胞外囊泡或受肿瘤影响的血小板（Alix-Panabières & Pantel，2021）。在本期EMBO Molecular Medicine中，Sauer等人(2022) 的报告证明了在异种移植模型中使用来自干血斑的 ctDNA 纵向监测疾病负担和反应的可行性。